venerdì, 30 luglio 2021
3 Novembre 2017

FDA Approval Sought for Frontline Brentuximab Vedotin for Hodgkin Lymphoma

November 2, 2017 – A supplemental new drug application has been submitted for brentuximab vedotin in combination with Adriamycin, vinblastine, dacarbazine (AVD) as a frontline treatment for advanced classical Hodgkin lymphoma, according to a statement from the company developing the CD30-targeted antibody-drug conjugate, Seattle Genetics. The application was based on findings from the phase III ECHELON-1 trial, which demonstrated superior progression-free … (leggi tutto)